He Jinfeng, Zhang Xuanping, Liu Linhong, Wang Yufei, Liu Renyu, Li Min, Gao Fuping
Department of Basic Medicine, Shanxi Medical University, Taiyuan 030001, China.
CAS Key Laboratory for Biomedical Effects of Nanomaterial and Nano Safety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.
J Funct Biomater. 2023 Mar 25;14(4):181. doi: 10.3390/jfb14040181.
Boron nitride nanoparticles have been reported for boron drug delivery. However, its toxicity has not been systematically elucidated. It is necessary to clarify their potential toxicity profile after administration for clinical application. Here, we prepared erythrocyte membrane-coated boron nitride nanoparticles (BN@RBCM). We expect to use them for boron neutron capture therapy (BNCT) in tumors. In this study, we evaluated the acute toxicity and subacute toxicity of BN@RBCM of about 100 nm and determined the half-lethal dose (LD50) of the particles for mice. The results showed that the LD50 of BN@RBCM was 258.94 mg/kg. No remarkable pathological changes by microscopic observation were observed in the treated animals throughout the study period. These results indicate that BN@RBCM has low toxicity and good biocompatibility, which have great potential for biomedical applications.
据报道，氮化硼纳米颗粒可用于硼药物递送。然而，其毒性尚未得到系统阐明。有必要在给药后阐明其潜在的毒性特征，以便用于临床应用。在此，我们制备了红细胞膜包被的氮化硼纳米颗粒（BN@RBCM）。我们期望将它们用于肿瘤的硼中子俘获疗法（BNCT）。在本研究中，我们评估了约100 nm的BN@RBCM的急性毒性和亚急性毒性，并确定了该颗粒对小鼠的半数致死剂量（LD50）。结果表明，BN@RBCM的LD50为258.94 mg/kg。在整个研究期间，经处理的动物通过显微镜观察未发现明显的病理变化。这些结果表明，BN@RBCM具有低毒性和良好的生物相容性，在生物医学应用方面具有巨大潜力。
